The Gothenburg-based company says its current working capital will not cover its needs over the next 12 months. If fully subscribed, the rights issue would fund operations into the first quarter of 2028 and finance EPIMODE through the end of patient recruitment. The warrants, worth up to SEK 250 million (series TO6) and SEK 150 million (series TO7), could finance the study through topline results and final reporting. Cereno aims to complete recruitment in 2027 and report topline results in the fourth quarter of 2028.

Proceeds will also go toward loan repayment, preparations for a Phase IIb trial with CS014 in pulmonary hypertension associated with interstitial lung disease (PH-ILD), and work ahead of a first-in-human trial with the preclinical candidate CS585.

“We recognize the concern and frustration that the financing situation and share price performance have caused among our shareholders, and we take this very seriously. With the intended rights issue, we are now taking an important step to create the conditions to continue advancing our clinical development,” says Sten R. Sörensen, CEO of Cereno Scientific.

Under the new financing agreement, Fenja extends SEK 105 million of an existing SEK 175 million convertible loan until November 2028 and provides a new loan facility of SEK 70 million. The remaining SEK 70 million of the loan will either be repaid in cash or converted into units in the rights issue, depending on how much other investors subscribe for.

An extraordinary general meeting will be held on December 15, 2026, to approve the changes needed for the issue. The subscription period is expected to run January 4–18, 2027.